Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: A systematic review and meta-analysis - 18/05/24
, Pooja Verma b, Shambo Samrat Samajdar c, Saibal Das d, eHighlights |
• | This meta-analysis evaluated the efficacy of vonoprazan as compared to conventional proton pump inhibitors (PPIs) for non-erosive esophagitis. |
• | Standard databases were searched and nine articles were included. |
• | As compared to PPI, vonoprazan led to a significant reduction in the gastrointestinal reflux disease (GERD) score, epigastric pain score, and post-prandial distress score. |
• | Vonoprazan could significantly improve symptoms in patients with non-erosive esophagitis or non-erosive GERD. |
Abstract |
Objective |
To evaluate the efficacy and safety of vonoprazan therapy as compared to conventional proton pump inhibitors (PPIs) or no vonoprazan for non-erosive esophagitis.
Methods |
A thorough search was conducted across databases. The primary outcome was to determine the mean variance in the gastroesophageal reflux disease (GERD) score after vonoprazan treatment. Secondary outcomes comprised alterations in the scores for epigastric pain and post-prandial distress, the proportion of patients displaying improvement, and the occurrence of adverse events. Pooled mean differences and relative risks were determined utilizing random effects models.
Results |
A total of 1,944 articles were screened and nine of them were included. As compared to PPI or no vonoprazan therapy, vonoprazan treatment led to a significant reduction in the GERD score [mean difference: -3.88 (95 % CI: -5.48, -2.28), p < 0.01, i2=95 %]. As compared to PPI or no vonoprazan therapy, vonoprazan treatment led to a significant reduction in the epigastric pain score [mean difference: -3.02 (95 % CI: -5.41, -0.63), p = 0.01, i2=75 %] and post-prandial distress score [mean difference: -2.82 (95 % CI: -3.51, -2.12), p < 0.01, i2=0 %] (all moderate GRADE evidence). Vonoprazan therapy was found to be safe.
Conclusion |
Treatment with vonoprazan could significantly improve symptoms in patients with non-erosive esophagitis or non-erosive GERD.
Le texte complet de cet article est disponible en PDF.Keywords : Gastroesophageal reflux disease (GERD), Non-erosive esophagitis, Proton pump inhibitors (PPIs), Vonoprazan
Plan
Vol 48 - N° 6
Article 102373- juin 2024 Retour au numéro
Article précédent
- Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease
- Severine Vermeire, Marla C. Dubinsky, Shervin Rabizadeh, John C Panetta, Elisabeth A. Spencer, Erwin Dreesen, Geert D'Haens, Thierry Dervieux, David Laharie
- Disease burden of Barrett's esophagus across the Paris metropolitan area
- Maximilien Barret, Mathis Collier, Viet-Thi Tran, Mourad Dellagi, Nathanael Beeker
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?